ArticleNature communications2019
LRIG1 is a pleiotropic androgen receptor-regulated feedback tumor suppressor in prostate cancer.
Erratum issuedOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- CircLRIG1 inhibits the malignant phenotypes of colorectal cancer cells by inactivating the NF-κB signaling through interaction with FUS.Discover oncology · 2026Article
- Deciphering the eRNA landscape and revealing target aberrant pathways in prostate cancer.BMC cancer · 2026Article
- High LRIG1 expression predicts lymph node metastasis in patients with uterine cervical cancer.FEBS open bio · 2025Article
- Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer.Cancer chemotherapy and pharmacology · 2025Article
- RBM15 facilitates osimertinib resistance of lung adenocarcinoma through m6A-dependent epigenetic silencing of SPOCK1.Oncogene · 2025Article
- Parabacteroides absconsus sp. nov., isolated from feces of a child with atopic dermatitis.Archives of microbiology · 2025Article
- Advancing Cancer Biology: Highlights from the 2025 FASEB SRC on Cellular Plasticity in Cancer.Cancer heterogeneity and plasticity · 2025Article
- Curcumin blunts epithelial-mesenchymal transition to alleviate invasion and metastasis of prostate cancer through the JARID1D demethylation.Cancer cell international · 2024Article
- HPV8-induced STAT3 activation led keratinocyte stem cell expansion in human actinic keratoses.JCI insight · 2024Article
- The clock gene BHLHE40 and atypical CCNG2 control androgen-induced cellular senescence as a novel tumor suppressive pathway in prostate cancer.Journal of experimental & clinical cancer research : CR · 2024Article
- Selective targeting of chemically modified miR-34a to prostate cancer using a small molecule ligand and an endosomal escape agent.Molecular therapy. Nucleic acids · 2024Article
- An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a tumor suppressive role in aggressive prostate cancer.Oncogene · 2024Article
- Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance.Frontiers in endocrinology · 2024Review
- Lrig1-expression confers suppressive function to CD4Nature communications · 2023Article
- Review
- LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor.Seminars in cancer biology · 2022Review
- Understanding and targeting prostate cancer cell heterogeneity and plasticity.Seminars in cancer biology · 2022Review
- Review
- Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis.Seminars in cancer biology · 2022Review
- LRIG1 is a positive prognostic marker in Merkel cell carcinoma and Merkel cell carcinoma expresses epithelial stem cell markers.Virchows Archiv : an international journal of pathology · 2021Article
Corrections and comments
- Erratum issued
Authors and funding
22 authors at 3 institutions in 2 countries.
Qiuhui LiDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
Bigang LiuDepartment of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Science Park, Smithville, TX, 78957, USA.
Hsueh-Ping ChaoDepartment of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Science Park, Smithville, TX, 78957, USA.
Yibing JiDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
Yue LuDepartment of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Science Park, Smithville, TX, 78957, USA.
Rashid MehmoodDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
Collene JeterDepartment of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Science Park, Smithville, TX, 78957, USA.
Taiping ChenDepartment of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Science Park, Smithville, TX, 78957, USA.ORCID http://orcid.org/0000-0002-2524-6440
John R MooreDepartment of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Science Park, Smithville, TX, 78957, USA.
Wenqian LiDepartment of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Science Park, Smithville, TX, 78957, USA.
Can LiuDepartment of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Science Park, Smithville, TX, 78957, USA.
Kiera RycajDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
Amanda TraczDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
Jason KirkDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
Tammy Calhoun-DavisDepartment of Epigenetics and Molecular Carcinogenesis, University of Texas M.D. Anderson Cancer Center, Science Park, Smithville, TX, 78957, USA.
Jie XiongDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
Qu DengDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
Jiaoti HuangDepartment of Pathology, Duke University of School of Medicine, Durham, NC, 27710, USA.
Barbara A FosterDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
Abhiram GokhaleDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.ORCID http://orcid.org/0000-0001-6157-1921
Xin ChenDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. dr_chenxin@163.com.
Dean G TangDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA. Dean.Tang@Roswellpark.org.ORCID http://orcid.org/0000-0001-5029-1174
Roswell Park Comprehensive Cancer Center · USThe University of Texas MD Anderson Cancer Center · USDuke University · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MWomen's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8MTwo-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6MNovel Therapeutic Strategies to Co-Target Undifferentiated Prostate Cancer (PCa) Stem Cells and Bulk PCa CellsR01CA240290 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 2019 to 2026
$3.1MTumor-Suppressive Functions and Molecular Regulation of LRIG1 in Prostate Cancer and CRPCR01CA237027 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI TANG, DEAN G. · 2019 to 2023
$2.2MDecoding NanogP8 in TumorigenesisR01CA155693 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI TANG, DEAN G. · 2012 to 2016
$1.6MSlow-cycling cells, therapy resistance and clinical implications in prostate cancerR21CA218635 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI TANG, DEAN G. · 2018 to 2019
$404kFlow Cytometry SorterS10OD025183 · OD · ROSWELL PARK CANCER INSTITUTE CORP · PI WALLACE, PAUL K · 2018 to 2018
$318kNCI NIH HHS P30 CA014236NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA155693NCI NIH HHS R01 CA237027NCI NIH HHS R01 CA240290NCI NIH HHS R21 CA218635NIH HHS S10 OD025183
Abstract
LRIG1 has been reported to be a tumor suppressor in gastrointestinal tract and epidermis. However, little is known about the expression, regulation and biological functions of LRIG1 in prostate cancer (PCa). We find that LRIG1 is overexpressed in PCa, but its expression correlates with better patient survival. Functional studies reveal strong tumor-suppressive functions of LRIG1 in both AR
Indexed as
AnimalsCell Line, TumorErb-b2 Receptor Tyrosine KinasesGene Expression Regulation, NeoplasticHumansMaleMembrane GlycoproteinsMice, Inbred NODMice, SCIDOncogene Protein p55(v-myc)Prostatic NeoplasmsProtein BindingReceptors, AndrogenSignal TransductionTumor Suppressor ProteinsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLRIG1 protein, humanMembrane GlycoproteinsOncogene Protein p55(v-myc)Receptors, AndrogenTumor Suppressor Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.